Pharmacom Biovet Stock Beneish M Score
| PHMB Stock | USD 0.0001 0.00 0.00% |
Pharmacom | Beneish M Score |
At this time, it appears that Pharmacom Biovet is an unlikely manipulator. The earnings manipulation may begin if Pharmacom Biovet's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Pharmacom Biovet executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Pharmacom Biovet's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.84
Beneish M Score - Unlikely Manipulator
Pharmacom Biovet Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Pharmacom Biovet's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 135.7 K | 129.2 K |
|
| |||||
| Property Plant Equipment | 86.3 K | 97.1 K |
|
| |||||
| Selling General Administrative | 475.5 K | 500.6 K |
|
| |||||
| Total Current Liabilities | 74.3 K | 70.8 K |
|
|
Pharmacom Biovet Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Pharmacom Biovet's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Pharmacom Biovet in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Pharmacom Biovet's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Pharmacom Biovet Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Total Assets |
|
About Pharmacom Biovet Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmacom Biovet's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmacom Biovet using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmacom Biovet based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pharmacom Biovet in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pharmacom Biovet's short interest history, or implied volatility extrapolated from Pharmacom Biovet options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pharmacom Biovet using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Pharmacom Biovet Piotroski F Score and Pharmacom Biovet Altman Z Score analysis. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Pharmacom Stock analysis
When running Pharmacom Biovet's price analysis, check to measure Pharmacom Biovet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacom Biovet is operating at the current time. Most of Pharmacom Biovet's value examination focuses on studying past and present price action to predict the probability of Pharmacom Biovet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacom Biovet's price. Additionally, you may evaluate how the addition of Pharmacom Biovet to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Pharmacom Biovet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.